Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 28;11(5):1305.
doi: 10.3390/biomedicines11051305.

GM1 Oligosaccharide Efficacy in Parkinson's Disease: Protection against MPTP

Affiliations

GM1 Oligosaccharide Efficacy in Parkinson's Disease: Protection against MPTP

Maria Fazzari et al. Biomedicines. .

Abstract

Past evidence has shown that the exogenous administration of GM1 ganglioside slowed neuronal death in preclinical models of Parkinson's disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons: however, the physical and chemical properties of GM1 (i.e., amphiphilicity) limited its clinical application, as the crossing of the blood-brain barrier is denied. Recently, we demonstrated that the GM1 oligosaccharide head group (GM1-OS) is the GM1 bioactive portion that, interacting with the TrkA-NGF complex at the membrane surface, promotes the activation of a multivariate network of intracellular events regulating neuronal differentiation, protection, and reparation. Here, we evaluated the GM1-OS neuroprotective potential against the Parkinson's disease-linked neurotoxin MPTP, which destroys dopaminergic neurons by affecting mitochondrial bioenergetics and causing ROS overproduction. In dopaminergic and glutamatergic primary cultures, GM1-OS administration significantly increased neuronal survival, preserved neurite network, and reduced mitochondrial ROS production enhancing the mTOR/Akt/GSK3β pathway. These data highlight the neuroprotective efficacy of GM1-OS in parkinsonian models through the implementation of mitochondrial function and reduction in oxidative stress.

Keywords: GM1 ganglioside; GM1 oligosaccharide; MPTP; Parkinson’s disease; neuroprotection; plasma membrane signaling.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Neuroprotective effects of GM1-OS in primary cultures of rat DA neurons injured with MPP+. On day 6 of culture, primary DA neurons were pre-incubated with GM1-OS (100 μM) for 1 h, before MPP+ exposure. Next, MPP+ (4 µM) was added to the culture medium. After 48 h, TH immunofluorescence was performed as described in the methods section. (a) Representative immunofluorescence images of TH-positive neurons (10X magnifications); (b) number of TH-positive neurons expressed as fold change over untreated control (CTRL) cells, as read-out of DA neuron survival; (c) length of TH-positive neurites in µm, expressed as fold change over untreated CTRL cells, for neurite network of DA neurons. All values are expressed as mean ± SEM (n = 6, **** p < 0.0001; *** p < 0.001; ** p < 0.01; One-way ANOVA followed by Tukey’s multiple comparisons test).
Figure 2
Figure 2
GM1-OS protected mouse CGNs injured with MPP+. On day 14 of culture, primary CGNs were pre-incubated with GM1-OS (100 μM) or water (CTRL) for 1 h before MPP+ exposure. Next, MPP+ (50 µM) or water was added to the culture medium for 24 h. (a) Phase contrast images of CGNs (20X magnification). Images are representative of four independent experiments (n = 4); (b) Viability assays: on the left LDH release, on the right MTT assay. All values are expressed as mean ± SEM (n = 4 independent experiments. *** p = 0.0005, **** p < 0.0001, one-way ANOVA followed by Tukey’s multiple comparisons test).
Figure 3
Figure 3
GM1-OS modulation of mTOR/Akt/GSK-3β pathway. WB of factors sustaining cell survival after 6 h and 24 h of MPP+ exposure: mTORP-Ser2448, AKTP-Ser473, GSK3βP-Ser9, and respective total proteins. Top: WB representative images; bottom: semiquantitative analysis of WB bands represented as fold change over CTRL. All values are expressed as mean ± SEM (n = 4 independent experiments. *** p = 0.0002, **** p < 0.0001, one-way ANOVA followed by Tukey’s multiple comparisons test).
Figure 4
Figure 4
GM1-OS counteracted mitochondrial O2•− increase induced by MPP+. On day 14 of culture, primary CGNs were pre-incubated with GM1-OS (100 μM) or water (CTRL) for 1 h before MPP+ exposure. Next, MPP+ (50 µM) or water was added to the culture and mitochondrial O2•− was evaluated by MitoSOX Red reagent. (a) Representative fluorescence images of CGNs after 1 h (top) or 6 h (bottom) of MPP+ administration (40× magnification). For each condition the small quadrants show single channel images with MitoSOX in red and Nuclei in blue and the big quadrant is the overlayed image (Scale bar: 50 µm); (b) quantification of the MitoSOX Red signal over nuclei number. All values are expressed as mean ± SEM (n = 3 independent experiments. * p < 0.01, *** p = 0.0006 **** p < 0.0001, one-way ANOVA followed by Tukey’s multiple comparisons test).

Similar articles

Cited by

References

    1. Poewe W., Seppi K., Tanner C.M., Halliday G.M., Brundin P., Volkmann J., Schrag A.E., Lang A.E. Parkinson disease. Nat. Rev. Dis. Primers. 2017;3:17013. doi: 10.1038/nrdp.2017.13. - DOI - PubMed
    1. Del Rey N.L., Quiroga-Varela A., Garbayo E., Carballo-Carbajal I., Fernandez-Santiago R., Monje M.H.G., Trigo-Damas I., Blanco-Prieto M.J., Blesa J. Advances in Parkinson’s Disease: 200 Years Later. Front. Neuroanat. 2018;12:113. doi: 10.3389/fnana.2018.00113. - DOI - PMC - PubMed
    1. Toomey C.E., Heywood W.E., Evans J.R., Lachica J., Pressey S.N., Foti S.C., Al Shahrani M., D’Sa K., Hargreaves I.P., Heales S., et al. Mitochondrial dysfunction is a key pathological driver of early stage Parkinson’s. Acta Neuropathol. Commun. 2022;10:134. doi: 10.1186/s40478-022-01424-6. - DOI - PMC - PubMed
    1. Gonzalez-Rodriguez P., Zampese E., Stout K.A., Guzman J.N., Ilijic E., Yang B., Tkatch T., Stavarache M.A., Wokosin D.L., Gao L., et al. Disruption of mitochondrial complex I induces progressive parkinsonism. Nature. 2021;599:650–656. doi: 10.1038/s41586-021-04059-0. - DOI - PMC - PubMed
    1. Lang M., Pramstaller P.P., Pichler I. Crosstalk of organelles in Parkinson’s disease - MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes. Mol. Neurodegener. 2022;17:50. doi: 10.1186/s13024-022-00555-7. - DOI - PMC - PubMed